Only Alli Remains After Glaxo’s OTC Transaction With Aspen
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline sells 19 OTC brands – worth about 1% of its consumer healthcare business – outside the U.S., Canada and Europe to South African firm Aspen Pharmacare. Weight-loss drug alli is GSK’s final remaining non-core OTC following the $263 million deal.
You may also be interested in...
Perrigo Expands Consumer Business Down Under, Rx Growth Looks Up
The OTC private-label sales leader acquires OTC and nutritional brands marketed down under. The Dublin-based firm hopes to add to its specialty generics offerings and its “promotable” brands with tuck-in acquisitions.
Perrigo Expands Consumer Business Down Under, Rx Growth Looks Up
The OTC private-label sales leader acquires OTC and nutritional brands marketed down under. The Dublin-based firm hopes to add to its specialty generics offerings and its “promotable” brands with tuck-in acquisitions.
Business & Finance In Brief: GSK | MJN | Actavis | ScripsAmerica
GSK spotlights oral care; Mead Johnson weighs China pricing effects; USANA builds on Asia enthusiasm; FMC lands omega-3 firm Epax; Actavis eyes additional M&A activity; ScripsAmerica grows OTC and Rx distribution.